NCT01750073 - Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 7, 2012

Primary Completion Date

May 1, 2022

Study Completion Date

June 30, 2026

Conditions

Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu NegativeHER2/Neu PositiveInvasive Breast CarcinomaProgesterone Receptor NegativeProgesterone Receptor PositiveStage IA Breast CancerStage II Breast CancerStage IIA Breast CancerStage IIB Breast CancerStage III Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerTriple-Negative Breast Carcinoma

Interventions

DRUG

Cyclophosphamide

Given IV

DRUG

Doxorubicin Hydrochloride

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Paclitaxel

Given IV

RADIATION

Radiation Therapy

Undergo RT

PROCEDURE

Therapeutic Conventional Surgery

Undergo mastectomy or breast conserving surgery

BIOLOGICAL

Trastuzumab

Given IV

Trial Locations (4)

68118

Nebraska Medicine-Village Pointe Cancer Center, Omaha

68123

Nebraska Medicine-Bellevue, Bellevue

68198

University of Nebraska Medical Center, Omaha

68803

CHI Health Saint Francis, Grand Island

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Nebraska

OTHER